Case Report: Serum methotrexate monitoring by immunoassay: confusion by by-product, confusion by antidote

Methotrexate is a commonly used agent in the treatment of many malignancies and rheumatologic/inflammatory diseases. Working by inhibiting dihydrofolate reductase and thereby preventing eventual formation of tetrahydrofolate, methotrexate inhibits synthesis of purines and thymidylate, therefore disa...

Full description

Bibliographic Details
Main Authors: Aditya Sharma, Philip Benoit, Frederick Lansigan, David Nierenberg
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-10-01
Series:Frontiers in Oncology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2023.1237178/full
_version_ 1797650825398452224
author Aditya Sharma
Philip Benoit
Frederick Lansigan
David Nierenberg
author_facet Aditya Sharma
Philip Benoit
Frederick Lansigan
David Nierenberg
author_sort Aditya Sharma
collection DOAJ
description Methotrexate is a commonly used agent in the treatment of many malignancies and rheumatologic/inflammatory diseases. Working by inhibiting dihydrofolate reductase and thereby preventing eventual formation of tetrahydrofolate, methotrexate inhibits synthesis of purines and thymidylate, therefore disabling a malignant cell’s ability to replicate. While it is able to effectively do this, methotrexate also holds potential for significant toxicity. Therefore, serum methotrexate monitoring is of utmost importance when administering the drug, particularly when high doses are used. Although there are several different measurement systems, the immunoassay is a commonly used monitoring system that may be prone to interference when using agents with similar carbon backbone as methotrexate, including folinic acid (leucovorin) at high doses, as well as in the setting of glucarpidase use and consequent methotrexate breakdown. However, adjusting leucovorin dosing policy and being aware of the potential of the immunoassay to be “confused” by similar molecules have allowed for the efficient and effective use of the immunoassay while preventing prolonged hospital stays at our institution.
first_indexed 2024-03-11T16:07:12Z
format Article
id doaj.art-5ea5472c19904c50bb4b3c7f0a19acdf
institution Directory Open Access Journal
issn 2234-943X
language English
last_indexed 2024-03-11T16:07:12Z
publishDate 2023-10-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Oncology
spelling doaj.art-5ea5472c19904c50bb4b3c7f0a19acdf2023-10-24T23:59:32ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2023-10-011310.3389/fonc.2023.12371781237178Case Report: Serum methotrexate monitoring by immunoassay: confusion by by-product, confusion by antidoteAditya Sharma0Philip Benoit1Frederick Lansigan2David Nierenberg3Department of Medicine, Dartmouth Health, Lebanon, NH, United StatesDivision of Hematology/Oncology, Dartmouth Cancer Center, Dartmouth Health, Lebanon, NH, United StatesDivision of Hematology/Oncology, Dartmouth Cancer Center, Dartmouth Health, Lebanon, NH, United StatesDepartment of Pharmacology, Dartmouth Health, Lebanon, NH, United StatesMethotrexate is a commonly used agent in the treatment of many malignancies and rheumatologic/inflammatory diseases. Working by inhibiting dihydrofolate reductase and thereby preventing eventual formation of tetrahydrofolate, methotrexate inhibits synthesis of purines and thymidylate, therefore disabling a malignant cell’s ability to replicate. While it is able to effectively do this, methotrexate also holds potential for significant toxicity. Therefore, serum methotrexate monitoring is of utmost importance when administering the drug, particularly when high doses are used. Although there are several different measurement systems, the immunoassay is a commonly used monitoring system that may be prone to interference when using agents with similar carbon backbone as methotrexate, including folinic acid (leucovorin) at high doses, as well as in the setting of glucarpidase use and consequent methotrexate breakdown. However, adjusting leucovorin dosing policy and being aware of the potential of the immunoassay to be “confused” by similar molecules have allowed for the efficient and effective use of the immunoassay while preventing prolonged hospital stays at our institution.https://www.frontiersin.org/articles/10.3389/fonc.2023.1237178/fullmethotrexateserummonitoringantidoteglucarpidaseleucovorin
spellingShingle Aditya Sharma
Philip Benoit
Frederick Lansigan
David Nierenberg
Case Report: Serum methotrexate monitoring by immunoassay: confusion by by-product, confusion by antidote
Frontiers in Oncology
methotrexate
serum
monitoring
antidote
glucarpidase
leucovorin
title Case Report: Serum methotrexate monitoring by immunoassay: confusion by by-product, confusion by antidote
title_full Case Report: Serum methotrexate monitoring by immunoassay: confusion by by-product, confusion by antidote
title_fullStr Case Report: Serum methotrexate monitoring by immunoassay: confusion by by-product, confusion by antidote
title_full_unstemmed Case Report: Serum methotrexate monitoring by immunoassay: confusion by by-product, confusion by antidote
title_short Case Report: Serum methotrexate monitoring by immunoassay: confusion by by-product, confusion by antidote
title_sort case report serum methotrexate monitoring by immunoassay confusion by by product confusion by antidote
topic methotrexate
serum
monitoring
antidote
glucarpidase
leucovorin
url https://www.frontiersin.org/articles/10.3389/fonc.2023.1237178/full
work_keys_str_mv AT adityasharma casereportserummethotrexatemonitoringbyimmunoassayconfusionbybyproductconfusionbyantidote
AT philipbenoit casereportserummethotrexatemonitoringbyimmunoassayconfusionbybyproductconfusionbyantidote
AT fredericklansigan casereportserummethotrexatemonitoringbyimmunoassayconfusionbybyproductconfusionbyantidote
AT davidnierenberg casereportserummethotrexatemonitoringbyimmunoassayconfusionbybyproductconfusionbyantidote